Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision badge updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedMinor site revision update to v3.4.2 from v3.4.1; no changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check38 days agoChange DetectedThe page now displays Revision: v3.4.1 and no longer displays Revision: v3.4.0.SummaryDifference0.1%

- Check52 days agoChange DetectedA glossary toggle was added; QC-related metadata labels were updated to display 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing the previous labels.SummaryDifference0.3%

- Check59 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4. No study content or critical information appears to have changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check88 days agoChange DetectedFooter now shows Revision: v3.3.3; references to HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.